scholarly journals Review of Small Cell Carcinomas of the Prostate

2011 ◽  
Vol 2011 ◽  
pp. 1-5 ◽  
Author(s):  
P. Furtado ◽  
M. V. A. Lima ◽  
C. Nogueira ◽  
M. Franco ◽  
F. Tavora
Keyword(s):  
Radiation Therapy ◽  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Neuroendocrine Carcinoma ◽  
Advanced Disease ◽  
Small Cell ◽  
High Grade ◽  
Small Cell Neuroendocrine Carcinoma ◽  
Rare Neoplasm ◽  
Carcinoma Of The Prostate

Small cell carcinoma of the prostate is a rare neoplasm, with only a few series hitherto reported. A little less than half of the cases are associated with conventional acinar adenocarcinoma, which are usually high grade. Although consensus has not been reached, the majority of patients with small cell neuroendocrine carcinoma of the prostate have advanced disease at diagnosis and disproportionally low PSA levels compared to patients with conventional acinar adenocarcinoma. Treatment consists mainly of chemotherapy associated with surgery. Radiation therapy is reserved for selected cases. This study reviews the most up-to-date information on small cell carcinomas of the prostate.

scholarly journals Long-Term Survival of a Patient with Metastatic Small-Cell Carcinoma of the Stomach Treated with Radiation Therapy

2015 ◽  
Vol 8 (3) ◽  
pp. 416-422
Author(s):  
Derek P. Bergsma ◽  
Luke O. Schoeniger ◽  
Laura Bratton ◽  
Alan W. Katz
Keyword(s):  
Radiation Therapy ◽  
Adjuvant Chemotherapy ◽  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Neuroendocrine Carcinoma ◽  
Small Cell ◽  
High Grade ◽  
Term Survival ◽  
Carcinoma Of The Stomach

Small-cell carcinoma (SCC), or high-grade neuroendocrine carcinoma of the stomach, is a rare subtype of extra-pulmonary SCC which is almost invariably lethal. Gastric SCC often presents with local symptoms indistinguishable from other primary stomach cancers; however, both regional and distant spread are common at the initial presentation. Depending on symptoms and patient performance status, treatment typically consists of chemotherapy or resection followed by adjuvant chemotherapy, as even patients with limited stage gastric SCC likely have micrometastatic disease at the time of diagnosis. In this case report, we describe the long-term survival of a 75-year-old male with recurrent oligometastatic high-grade neuroendocrine carcinoma of the stomach treated with radiation therapy (RT) alone. He presented with abdominal pain and dyspepsia and was found to have a 6 cm locally invasive node-positive gastric SCC initially treated with extensive surgical resection. He was not a candidate for adjuvant chemotherapy, and surveillance imaging subsequently confirmed metachronous liver and local recurrences within 1 year after surgery, which were managed with stereotactic body RT and conventional radiation, respectively. An additional para-aortic nodal recurrence was treated with intensity-modulated radiotherapy 7 years after surgery with good response. He tolerated all RT courses without notable radiation-related toxicity and remains in complete remission 11 years after initial diagnosis.

Distinction of High-Grade Neuroendocrine Carcinoma/Small Cell Carcinoma From Conventional Urothelial Carcinoma of Urinary Bladder

2011 ◽  
Vol 19 (5) ◽  
pp. 395-399 ◽  
Author(s):  
Sherry Thompson ◽  
Maureen Cioffi-Lavina ◽  
Jennifer Chapman-Fredricks ◽  
Carmen Gomez-Fernandez ◽  
Gustavo Fernandez-Castro ◽  
...  
Keyword(s):  
Urinary Bladder ◽  
Urothelial Carcinoma ◽  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Neuroendocrine Carcinoma ◽  
Small Cell ◽  
High Grade

scholarly journals Primary Neuroendocrine Tumor of the Scrotum: An Uncommon Site for a Rare Tumor

2021 ◽  
Vol 9 ◽  
pp. 232470962110087
Author(s):  
Komal Akhtar ◽  
Vrinda Vyas ◽  
Prashanth Ashok Kumar ◽  
James Corines ◽  
Gustavo de la Roza ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Rare Case ◽  
Advanced Disease ◽  
Small Cell ◽  
High Grade ◽  
Rare Tumor ◽  
Off Label ◽  
History Of ◽  
To Receive

Neuroendocrine tumors (NETs) are a heterogeneous group of tumors developing from neural crest cells, with numerous sites of origin, commonly the gastrointestinal and genitourinary tracts. NETs of the genitourinary tract are more common in women. Small cell carcinoma of the prostate or testicular carcinoid are the NETs in male. In this article, we present a rare case of NET of the scrotum. Our patient was a 47-year-old male with a history of complicated pilonidal cysts resulting in chronic scrotal wounds. Biopsy of a large nonhealing scrotal wound revealed a high-grade neuroendocrine carcinoma with features most suggestive of small cell carcinoma. Presenting with advanced disease at diagnosis, he was started on systemic therapy and unfortunately progressed through multiple lines of treatment, including CAPTEM (capecitabine and temozolomide). Unfortunately, due to multiple logistical reasons, the patient was unable to receive the then off-label immunotherapy based on DART (Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors) trial. He, unfortunately, succumbed to his disease within months of diagnosis.

370 Pure Primary Small Cell Carcinoma of the Prostate: A Rare Entity

2021 ◽  
Vol 108 (Supplement_2) ◽  
Author(s):  
C Desai ◽  
A Bhojwani ◽  
J Parkin
Keyword(s):  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Clinical Symptoms ◽  
Positive Family History ◽  
Malignant Neoplasm ◽  
Small Cell ◽  
Whole Body ◽  
Carcinoma Of The Prostate ◽  
Patient Reported ◽  
Prostate Cancers

Abstract Introduction We report a case of small cell carcinoma of the prostate (SCCP) which is a rare, high-grade malignant neoplasm accounting for 1% of all prostate cancers (CPa). Case Presentation A 56-year-old male patient initially presented to primary care with a six-month history of frequency, nocturia and pain in the perineal region when seated. A positive family-history for CPa was noted, serum PSA was 11.58, and a rectal examination found a large, irregular mass. He was treated with antibiotics for possible prostatitis and referred to the colorectal team. MRI rectum confirmed a mass between the prostate and rectum, which was found to be pure SCCP on biopsy. Whole-body scanning found multiple lung and pelvic metastases. The patient was commenced on six cycles of Etoposide and Carboplatin therapy. The patient reported that his pelvic discomfort has improved following the first cycle. Conclusions SCCP metastasizes early and therefore the clinical presentation is often in an advanced stage. It is noted that there is limited value of serum PSA for SCCP diagnosis. Instead, pathological examinations and MRI rectum are vital. In terms of treatment, chemotherapy provides relief of the clinical symptoms and its use is in in accordance with the 2016 National Comprehensive Cancer Network guidelines.

Long-Term Outcomes of Organ Preservation in Patients with Small Cell Carcinoma of the Bladder

2015 ◽  
Vol 94 (4) ◽  
pp. 401-405 ◽  
Author(s):  
Jairam R. Eswara ◽  
Niall M. Heney ◽  
Chin-Lee Wu ◽  
W. Scott McDougal
Keyword(s):  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Metastatic Disease ◽  
Advanced Disease ◽  
Chemical Exposure ◽  
Small Cell ◽  
Cancer Specific Survival ◽  
Entire Cohort ◽  
Aggressive Disease ◽  
Carcinoma Of The Bladder

Background: Small cell carcinoma of the bladder is an uncommon but clinically aggressive disease. There is no standard surgical or medical management for the disease. Methods: Between 1995 and 2009, 28 patients underwent transurethral resection (TUR) and/or cystectomy, chemotherapy, and/or radiation for small cell carcinoma of the bladder at our institution. Results: The median follow-up for survivors was 34 months. Patients presented most often with muscle-invasive disease (T2-4 - 89%), and 21% had lymph node/distant metastases. Tobacco use and chemical exposure were noted in 64 and 4% of patients, respectively. Patients with T1-2N0M0 had a median survival of 22 months compared to 8 months for those with more advanced disease (p = 0.03). Patients with T3-4 or nodal/metastatic disease who were given chemotherapy had an improved survival compared to those with T3-4 or nodal/metastatic disease who did not undergo chemotherapy (13 vs. 4 months, p = 0.005). The median time to recurrence of the entire cohort was 8 months, overall and cancer-specific survival was 14 months, and 5-year survival was 11%. Conclusions: Small cell carcinoma of the bladder is an aggressive disease with poor outcomes. Patients with T1-2N0M0 disease survived longer than those with advanced disease. Patients with T3-4 or nodal/metastatic disease had improved survival with chemotherapy.

Radiation therapy for limited stage small cell carcinoma of the lung

1986 ◽  
Vol 12 ◽  
pp. 156-157
Author(s):  
James O. Gates ◽  
Rao V.P. Mantravadi ◽  
John N. Crawford ◽  
Deepchand Bajpai ◽  
John D. Trenkner ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Small Cell ◽  
Limited Stage
Sign in / Sign up

Export Citation Format

Share Document